Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.43 |
| ▸ | TPH1 | P17752 | 2/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485771 | 0.85 | GRIA1 (0.52) | GRIA1GRIA3GRIA4GRIK5 | |
| SCHEMBL615017 | 0.85 | GRIA1 (0.52) | GRIA1GRIA3GRIA4GRIK5 | |
| SCHEMBL939749 | 0.85 | GRIA1 (0.52) | GRIA1GRIA3GRIA4GRIK5 | |
| SCHEMBL5298700 | 0.82 | GRIA1 (0.47) | GRIA1GRIA3GRIA4GRIK5 | |
| SCHEMBL4757741 | 0.81 | GRIA1 (0.48) | GRIA1GRIA3GRIA4GRIK5 | |
| SCHEMBL6255381 | 0.81 | GRIA1 (0.48) | GRIA1GRIA3GRIA4GRIK5 | |
| SCHEMBL5605868 | 0.79 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL43515 | 0.79 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2652715 | 0.79 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2651847 | 0.79 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140341814-A1 | COMPOUNDS MODULATORS OF VEGF ACTIVITY AND USES THEREOF | ADVANCED ACCELERATOR APPLICATIONS S.A. | 2014-11-20 | — | — | US | disclosed |
| US-20120040025-A9 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | IRONWOOD PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20100215779-A1 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | IRONWOOD PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040025-A9 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | SLC10A2, SLC10A1, SLC26A3 | GRIA1 2882/4885GRIA3 2581/4885GRIA4 2598/4885 |
| US-20100215779-A1 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | SLC10A2, SLC10A1, SLC26A3 | GRIA1 2882/4885GRIA3 2581/4885GRIA4 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.